Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUART: Durvalumab After Radiation in Stage III Unresectable NSCLC Ineligible for Chemotherapy
2019-004336-31Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Grade 3 and Grade 4 PRAEs. Started May 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-004336-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004336-31.